At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 629 enrolled
Drug / intervention
QMF149 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, 12-week Treatment, Parallel-group Study to Evaluate the Efficacy and Safety of QMF149 (150 µg/160 µg o.d.) Compared With Salmeterol Xinafoate/Fluticasone Propionate (50 µg/500 µg b.i.d.) in Patients With Chronic Obstructive Pulmonary Disease
In Brief
A Phase 2 clinical trial evaluating QMF149 and Salmeterol for COPD. Completed, enrolled 629 participants across 115 sites in 18 countries.
Detailed Summary
To compare the efficacy, safety and pharmacokinetics of QMF149 delivered via Concept1 to salmeterol xinafoate/fluticasone propionate delivered via Accuhaler in adult patients with COPD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesAustralia, Belgium, Bulgaria, Denmark, Finland, Germany, Greece, Hong Kong, Hungary, Israel, Malaysia, Poland, Romania, Singapore, South Africa, Spain, Sweden, Thailand
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartNov 2012
Primary CompletionSep 2013
TodayJul 2026
First PostedJul 10, 2012
Enrollment StartNov 1, 2012
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.0 years ago
Interventions
QMF149drug
delivered via Concept1 device
Salmeteroldrug
delivered via Accuhaler®